AMGN

Amgen
D

AMGN

Arincen67/100B

Amgen executives and insider trading

Robert A. Bradway reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Amgen's insiders sold 34,240 shares for 13.02M USD in 8 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
8
Shares sold
34,240
Value sold
13.02M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
0
0
3 months
0
0
6 months
2.48M USD
0
1 year
13.02M USD
0
2 years
40.52M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Esteban Santos Executive Vice President of Operations5824,2919.21M USD—26 Feb 202682,847
Nancy A. Grygiel SVP & CCO—3,8761.36M USD—6 Aug 20269,310
Rachna Khosla SVP, Business Development—3,2521.35M USD—13 Aug 20267,656
Derek Miller SVP, Human Resources—1,821733.03K USD—6 Aug 202614,531
Matthew C. Busch Chief Accounting Officer & Vice President of Finance511,000375.79K USD—19 Feb 20265,080

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
13 Aug 2026Rachna KhoslaSale1,252416.43521.36K USD6,404Form 4
11 Aug 2026Rachna KhoslaSale2,000412.57825.13K USD6,404Form 4
6 Aug 2026Derek MillerSale1,821402.54733.03K USD12,462Form 4
6 Aug 2026Nancy A. GrygielSale1,000402.16402.16K USD7,340Form 4
4 May 2026Nancy A. GrygielSale1,237323.73400.45K USD7,009Form 4
26 Feb 2026Esteban SantosSale24,291379.129.21M USD76,618Form 4
19 Feb 2026Matthew C. BuschSale1,000375.79375.79K USD3,423Form 4
20 Nov 2025Nancy A. GrygielSale1,639337.26552.77K USD7,225Form 4
12 Nov 2025Rachna KhoslaSale890336.24299.26K USD7,082Form 4
12 Nov 2025Murdo GordonSale6,879336.832.32M USD41,923Form 4
20 Aug 2025Nancy A. GrygielSale1,267296.99376.28K USD7,209Form 4
5 Jun 2025Rachna KhoslaSale1,500289.68434.52K USD8,162Form 4
2 May 2025Matthew C. BuschSale1,000279.69279.69K USD4,034Form 4
21 Feb 2025David M ReeseSale25,225304.447.68M USD36,922Form 4
19 Feb 2025Esteban SantosSale8,711292.842.55M USD71,546Form 4

Common questions about Amgen's executives and insiders

Source: Financial Modeling PrepVerified against SEC filings